Chemist Carolyn Bertozzi returns to Eli Lilly's board of directors

Eli Lilly and Company elected Carolyn R. Bertozzi, Ph.D., to its board of directors effective Dec. 8, 2025, the Indianapolis-based drugmaker said in a press release ^[1]. She is returning to a seat she held from 2017 to 2021 ^[1].

Bertozzi, a Stanford University chemist, will sit on two board committees: Science and Technology, and Ethics and Compliance ^[1]. Lilly's release describes her as a Nobel Prize-winning chemist; it does not state which year she won the award or what research was recognized ^[1].

"On behalf of Lilly and the entire board, I would like to welcome Carolyn back to Lilly," said David A. Ricks, the company's chair and chief executive officer ^[1]. "As we continue to pioneer new approaches in oncology and immunology, her perspective will be invaluable," he said ^[1].

At Stanford, Bertozzi is the Baker Family director of Sarafan ChEM-H and holds the Anne T. and Robert M. Bass professorship in the School of Humanities and Sciences, with courtesy professorships in Chemical and Systems Biology and in Radiology ^[1]. She is an investigator at the Howard Hughes Medical Institute and a member of the National Academy of Medicine, the National Academy of Sciences and the American Academy of Arts and Sciences ^[1].

Lilly describes its research priorities as redefining diabetes care, treating obesity and its long-term effects, fighting Alzheimer's disease, addressing immune system disorders and turning hard-to-treat cancers into manageable diseases ^[1]. The announcement does not name individual medicines or link Bertozzi's return to any specific product or program ^[1].

The release does not say how many directors sit on the board, whether Bertozzi will be considered an independent director, how long her term lasts, or how she will be compensated ^[1]. It also does not name the board's other members ^[1]. Those details have not been disclosed.

Why it matters for patients

A change in board membership does not change anyone's prescription. Nothing in the announcement affects the approval status, manufacturing supply, list price, insurance coverage or pharmacy availability of any medicine, and no such change has been reported ^[1].

Directors vote on company strategy, executive pay and major transactions, and committee work can put a director close to decisions about which research programs move forward. Even so, the announcement does not describe the Science and Technology committee's duties, how often it meets, or how much influence any one director has, so the practical effect on what Lilly develops is not established ^[1].

For people managing a GLP-1 prescription, the questions that come up week to week — refills, prior authorizations, copays and whether a dose is in stock — are settled by prescribers, pharmacies, insurers and manufacturers' patient support programs, not by who sits on a drugmaker's board.

What happens next

Bertozzi's election took effect Dec. 8, 2025, and her two committee assignments are already in place ^[1]. The release does not give the length of her term, list upcoming board or committee meeting dates, or say whether shareholders will vote on her seat at a future annual meeting ^[1]. No shareholder vote date has been disclosed.

The announcement also carries a standard cautionary statement noting risks and uncertainties in Lilly's research, development and manufacturing work that could cause results to differ from the company's expectations ^[1].